Benchling
Funding History
| Series D · 05/2020 | $850M |
|---|---|
| Series E · 04/2021 | $4.0B |
| Series F · 11/2021 | $6.1B |
About
Benchling provides a cloud-based software platform for biotechnology research and development, giving scientists tools for experiment design, electronic lab notebooks, molecular biology workflows, and R&D data management.
- CEO
- Sajith Wickramasekara
- Headquarters
- San Francisco, California
- Founded
- 2012
- Employees
- 605
- Website
- benchling.com
Overview
Benchling is a cloud-based software platform for biotechnology research and development, providing scientists with tools for experiment design, electronic lab notebooks, molecular biology, and data management across the drug-discovery and development lifecycle. Founded in 2012 by MIT graduates Sajith Wickramasekara and Ashu Singhal, the company is headquartered in San Francisco. Benchling raised a $200 million Series E in April 2021 at a $4 billion valuation, followed by a $100 million Series F in November 2021 co-led by Franklin Templeton and Altimeter Capital at a $6.1 billion valuation — its most recent disclosed priced round as of this writing. The company has continued to expand its product line through acquisitions, including antibody-discovery software maker PipeBio in October 2024, and AI-focused startups ReSync Bio and Sphinx Bio in August 2025 to build out its AI roadmap for drug discovery. In October 2025, Benchling announced a partnership with Anthropic to bring Claude's AI capabilities into its platform via the Model Context Protocol. Benchling remains privately held with no announced IPO date.
Private securities are speculative, illiquid, and involve risk of complete loss of principal. You should be prepared to hold private securities for an extended period; there is no assurance of a secondary market, an IPO, or other liquidity event. You are fully responsible for conducting your own due diligence. Pricing is indicative — nothing here is an offer of securities.